
Canaery helps organizations detect hazardous or relevant substances by analyzing an object’s scent fingerprint in plain English. The company builds a neurotechnology-based neural interface and a networked odor database, pairing enhanced working-animal signals with SaaS data and machine learning to classify chemical signatures. Its product combines hardware neural interfaces, scent fingerprinting models, and a cloud platform for storing and querying detectable odors. Target use cases include border and transportation security, medical screening, and invasive pest inspection, positioning it as a B2B neurotech and SaaS provider in safety and diagnostics markets.

Canaery helps organizations detect hazardous or relevant substances by analyzing an object’s scent fingerprint in plain English. The company builds a neurotechnology-based neural interface and a networked odor database, pairing enhanced working-animal signals with SaaS data and machine learning to classify chemical signatures. Its product combines hardware neural interfaces, scent fingerprinting models, and a cloud platform for storing and querying detectable odors. Target use cases include border and transportation security, medical screening, and invasive pest inspection, positioning it as a B2B neurotech and SaaS provider in safety and diagnostics markets.
What they do: Build a nose–computer interface that pairs animal olfaction, neural interfaces, and AI to classify scent fingerprints
Primary customers / use cases: Border/transport security, contraband detection, pest inspection, and medical screening
Founded: 2020
Reported team size: About 10 employees
Known funding: $4,000,000 seed (Jul 1, 2022); additional seed activity Jul 25, 2023; total disclosed investors listed
Detection and classification of chemical signatures (explosives, narcotics, pests, disease markers) using biological olfaction augmented by neurotech and AI.
2020
Biotechnology
4000000
Seed round announced July 1, 2022
Seed round activity reported July 25, 2023; amount undisclosed in provided evidence
“Investors include Arkitekt Ventures, Asymmetry Ventures, Breakout Ventures, DeepWork Capital, Dolby Family Ventures, Florida Opportunity Fund, IndieBio, KdT Ventures, SOSV”